Drug Trial Radar · NCT03259789
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Last checked: Nov 20, 2026Latest source record: Jul 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
351
Actual
Start
Nov 28, 2017
Primary completion
Jan 23, 2019
Study completion Jan 23, 2019
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Conditions
- Type2 Diabetes Mellitus
Interventions
Bexagliflozin tablets, 20 mgDrug
Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Bexagliflozin tablets, placeboDrug
Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
Bexagliflozin tablets, 20 mgDrug
Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 24 for Double-blind GroupTime frame: Baseline to week 24
- Change From Baseline in HbA1c at Week 24 for High Glycemic GroupTime frame: Baseline to week 24
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Research Site 1232
Birmingham, Alabama
Clinical Research Site 1378
Birmingham, Alabama
Clinical Research Site 1269
Foley, Alabama
Clinical Research Site 1363
Little Rock, Arkansas
Clinical Research Site 1381
Anaheim, California
Clinical Research Site 1375
North Hollywood, California
Clinical Research Site 1365
Norwalk, California
Clinical Research Site 1382
Norwalk, Connecticut
Clinical Research Site 1372
Hollywood, Florida
Clinical Research Site 1362
Palm Springs, Florida
Clinical Research Site 1373
Pembroke Pines, Florida
Clinical Research Site 1376
Nampa, Idaho
Clinical Research Site 1366
Chicago, Illinois
Clinical Research Site 1294
New Orleans, Louisiana
Clinical Research Site 1374
St Louis, Missouri
Clinical Research Site 1370
Las Vegas, Nevada
Clinical Research Site 1009
Berlin, New Jersey
Clinical Research Site 1037
Trenton, New Jersey
Clinical Research Site 1286
Albuquerque, New Mexico
Clinical Research Site 1368
New York, New York
Clinical Research Site 1275
The Bronx, New York
Clinical Research Site 1019
Portland, Oregon
Clinical Research Site 1379
Gonzales, Texas
Clinical Research Site 1369
Houston, Texas
Clinical Research Site 1371
San Antonio, Texas
Clinical Research Site 1360
San Antonio, Texas
Clinical Research Site 6040
Fukuoka, Japan
Clinical Research Site 6043
Kyoto, Japan
Clinical Research Site 6015
Osaka, Japan
Clinical Research Site 6045
Tokyo, Japan
Clinical Research Site 6047
Tokyo, Japan
Clinical Research Site 6048
Nagoya, Aichi-ken, Japan
Clinical Research Site 6050
Sapporo, Hokkaido, Japan
Clinical Research Site 6041
Koga, Ibaraki, Japan
Clinical Research Site 6029
Atsugi, Kanagawa, Japan
Clinical Research Site 6051
Kamakura, Kanagawa, Japan
Clinical Research Site 6020
Yokohama, Kanagawa, Japan
Clinical Research Site 6055
Tokyo, Meguro, Japan
Clinical Research Site 6046
Higashiosaka, Osaka, Japan
Clinical Research Site 6033
Kashihara, Osaka, Japan
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.